1stOncology™: Cancer Intelligence Service – Page 15763 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Bayer: Sales and earnings increased

On October 26, 2017 Bayer reported that the third quarter of 2017 marked a period of further strategic and operational progress for the Bayer Group (Press release, Bayer, OCT 26, 2017, View Source [SID1234521222]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

“Last quarter we took some important strategic steps,” said Werner Baumann, Chairman of the Board of Management, when he presented the interim report for the third quarter on Thursday. Bayer has made very good progress toward its goal of achieving full separation from Covestro in the medium term, he noted. As regards the planned acquisition of Monsanto, Baumann explained how the agreement to sell selected Crop Science businesses to BASF marked another important step. Bayer recorded an increase in sales (currency- and portfolio adjusted – Fx & portfolio adj.) and earnings at Pharmaceuticals in the third quarter. Business at Consumer Health declined, as expected. At Crop Science and Animal Health, sales moved ahead (Fx & portfolio adj.), while EBITDA before special items decreased year on year.

The agreed sale of selected Crop Science businesses to BASF for EUR 5.9 billion is subject to the approval of the antitrust authorities. The transaction is also dependent on the successful closing of Bayer’s acquisition of Monsanto. “With this agreement, we are actively addressing the authorities’ possible concerns regarding the planned acquisition of Monsanto. However, it is not an attempt to preempt any decisions by the regulatory authorities,” Baumann stressed. Bayer continues to work closely with the authorities with the aim of facilitating a successful closing of the transaction by early 2018.

Bayer has reduced its direct interest in Covestro to 24.6 percent, and is declining to exercise certain voting rights at the Covestro Annual General Meeting. “We have thus ceded de facto control over Covestro and deconsolidated it,” Baumann explained. The remaining shares of Covestro are now recognized in the statement of financial position using the equity method. The continuing operations of the Bayer Group are now comprised exclusively of the Life Science businesses. The financial information for the preceding quarters and the prior-year figures have been restated accordingly.

Group sales in the third quarter of 2017 declined by 2.8 percent to EUR 8,025 million (Q3 2016: EUR 8,258 million). Adjusted for currency and portfolio effects, sales advanced 1.2 percent. EBITDA before special items improved by 4.1 percent to EUR 2,204 million (Q3 2016: EUR 2,118 million). Negative currency effects diminished earnings by around EUR 100 million. EBIT came to EUR 1,388 million, matching the prior-year period (Q3 2016: EUR 1,397 million). This figure reflected net special charges of EUR 249 million (Q3 2016: EUR 125 million), consisting primarily of expenses in connection with the agreed acquisition of Monsanto, provisions for legal risks, and efficiency improvement programs. EBIT before special items advanced by 7.6 percent to EUR 1,637 million (Q3 2016: EUR 1,522 million).

Net income came to EUR 3,881 million (Q3 2016: EUR 1,187 million). This figure includes a gain of EUR 2.8 billion resulting from the deconsolidation of Covestro and the presentation of the Covestro Group as an associate for the first time. Earnings per share (total) increased to EUR 4.45 (Q3 2016: EUR 1.43). Core earnings per share from continuing operations fell by 3.9 percent to EUR 1.47 (Q3 2016: EUR 1.53). This is due primarily to the difference in the number of shares, which grew significantly in 2017 as a result of the mandatory convertible notes issued in November 2016. Had the number of shares remained the same, core earnings per share would have improved by 1.4 percent.

Net cash provided by operating activities (total) declined by 11.2 percent in the third quarter of 2017, to EUR 2,711 million (Q3 2016: EUR 3,053 million). Net financial debt declined by half to EUR 4.7 billion compared with June 30, 2017, due mainly to cash inflows from operating activities, inflows of EUR 2.2 billion from the sale of Covestro shares, and a reduction of EUR 0.5 billion from the deconsolidation of the Covestro Group.

Pharmaceuticals: Key growth products continue to deliver strong performance

Sales of prescription medicines (Pharmaceuticals) increased by 2.3 percent (Fx & portfolio adj.) to EUR 4,065 million. “Our key growth products again delivered strong performance,” Baumann said. The oral anticoagulant Xarelto, the eye medicine Eylea, the cancer drugs Xofigo and Stivarga, and the pulmonary hypertension treatment Adempas posted total combined sales of EUR 1,522 million, up 13.2 percent (Fx adj.). Xarelto sales increased by 6.6 percent (Fx adj.), with growth driven by gains in Europe and Asia. Sales in the United States, where Xarelto is marketed by a subsidiary of Johnson & Johnson, increased by a double-digit percentage. However, license revenues – recognized as sales at Bayer– were level with the prior-year quarter, in part due to a shift between reporting periods. Sales of Eylea advanced significantly (Fx adj. plus 19.9 percent), due particularly to a substantial expansion of volumes in Japan, Europe and Canada. Xofigo also posted strong gains (Fx adj. plus 24.9 percent), with business continuing to benefit from a successful market launch in Japan and higher demand in Europe. Bayer substantially increased sales of Stivarga (Fx adj. plus 27.7 percent), especially in the United States and Japan. Adempas also showed strong growth (Fx adj. plus 19.3 percent), especially in the United States.

Business with the Kogenate/Kovaltry blood-clotting medicines was down significantly year on year (Fx adj. minus 25.9 percent) due primarily to lower order volumes for the active ingredient placed by a distribution partner. After adjusting for this development, sales were at the prior-year level. In contrast, the hormone-releasing intrauterine devices of the Mirena product family delivered encouraging performance (Fx adj. plus 8.4 percent).

EBITDA before special items of Pharmaceuticals increased by 5.1 percent to EUR 1,493 million. This development was largely the result of higher volumes and a lower cost of goods sold. In addition, the division recorded a positive earnings effect from a receivable in the mid-double-digit millions as one of its distribution partners for Kogenate did not fulfill its purchase obligation. In contrast, negative currency effects diminished earnings by about EUR 60 million.

Weak development at Consumer Health, as expected

Sales of Consumer Health in the third quarter fell by 2.9 percent (Fx & portfolio adj.) to €1,320 million. “As anticipated, we recorded a weak development of business with our self-care products,” Baumann said. The decline in sales in North America was largely due to the market environment remaining challenging in the United States. The negative development in Europe is primarily the result of weaker business in Russia after a strong previous quarter. On a currency-adjusted basis, the division increased sales in Latin America and attained the prior-year level in Asia/Pacific.

The antihistamine Claritin achieved a marked increase in sales (Fx adj. plus 9.3 percent) compared with a weak prior-year quarter, primarily in China and the United States. Sales of the analgesic Aspirin edged higher. Including business with Aspirin Cardio, which is reported under Pharmaceuticals, sales advanced by 7.9 percent (Fx adj.). Business with the Bepanthen/Bepanthol wound and skin care products developed positively (Fx adj. plus 6.1 percent), especially in Europe. Sales of the sunscreen product Coppertone declined substantially (Fx adj. minus 44.6 percent), mainly due to ongoing strong competitive pressure in the United States.

EBITDA before special items of Consumer Health declined by a substantial 16.5 percent to EUR 274 million. The fall in earnings is primarily due to lower volumes and a higher cost of goods sold, which largely resulted from inventory write-offs and the underutilization of production facilities. In addition, currency effects diminished earnings by around EUR 10 million. Earnings also included one-time gains in the amount of around EUR 30 million that mainly related to the sale of non-core brands.

Crop Science posts significant gains in North America and Asia/Pacific

Third-quarter sales of the agricultural business (Crop Science) moved ahead by 2.7 percent (Fx & portfolio adj.) to EUR 2,031 million. Crop Science achieved gratifying business development in North America and Asia/Pacific, where sales rose by 9.8 percent (Fx adj.) and 7.4 percent (Fx adj.), respectively. Sales in Europe/Middle East/Africa and Latin America matched the prior-year level. “On the positive side, we were able to reduce provisions for product returns in Brazil, which shows that the measures we have implemented to normalize the situation in Brazil are taking hold,” Baumann said. In that country, Bayer had to establish provisions in the second quarter due to unexpectedly high inventories of crop protection products.

At Crop Protection, the Insecticides business delivered very positive performance, with sales rising by 13.2 percent (Fx & portfolio adj.). Sales declined at Fungicides (Fx & portfolio adj. minus 6.3 percent), Herbicides (Fx & portfolio adj. minus 1.9 percent) and SeedGrowth (Fx & portfolio adj. minus 1.1 percent). In contrast, Seeds (which also includes the traits business) reported strong gains, with sales rising by 29.6 percent (Fx & portfolio adj.). Environmental Science posted increased sales due to product deliveries to the acquirer of the consumer business divested in the fourth quarter of 2016 (Fx & portfolio adj. plus 6.8 percent).

EBITDA before special items of Crop Science decreased by 3.5 percent to EUR 307 million in the third quarter of 2017. Lower selling prices and a negative currency effect of around EUR 20 million stood against an increase in other operating income, a decline in the cost of goods sold and a decrease in selling expenses. Positive effects in the mid-double-digit millions were recorded in conjunction with the accounting measures taken in the previous quarter in Brazil.

Animal Health: Sales edge higher in challenging market environment

Sales of the Animal Health business rose by 1.4 percent (Fx and portfolio adj.) to EUR 359 million in a weak market environment overall. The business unit achieved considerable gains in the North America region on a currency-adjusted basis, thanks partly to the Cydectin product portfolio acquired in January 2017. Sales of the Advantage family of flea, tick and worm control products were down 3.3 percent (Fx adj.) year on year, mainly as a result of higher competitive pressure in Europe. The Seresto flea and tick collar continued to post double-digit-percentage sales growth, with sales rising by 17.1 percent (Fx adj.). EBITDA before special items of Animal Health declined by 9.0 percent to EUR 81 million, in part due to higher selling expenses and a currency loss of around EUR 5 million.

Nine-month sales edge higher

Group sales in the first nine months of 2017 rose by 1.1 percent (Fx & portfolio adj. plus 1.1 percent) to EUR 26,419 million (9M 2016: EUR 26,120 million). EBITDA before special items came in at EUR 7,505 million, matching the prior-year level (9M 2016: EUR 7,512 million). Net income amounted to EUR 7,188 million (9M 2016: EUR 4,078 million). Earnings per share (total) improved to EUR 8.24 (9M 2016: EUR 4.93), while core earnings per share from continuing operations were down 4.5 percent year on year at EUR 5.33 (9M 2016: EUR 5.58). This is due primarily to the difference in the number of shares, which grew significantly in 2017 as a result of the mandatory convertible notes issued in November 2016. Had the number of shares remained the same, core earnings per share would have improved by 0.7 percent.

Group outlook for 2017 confirmed based on change in structure

Following the deconsolidation of the company, Covestro will be presented as a discontinued operation and is thus, as of the fourth quarter of 2017, treated only as an equity method investment in the forecast. The Bayer Group’s continuing operations thus reflect the values previously referred to under Life Sciences. For the fourth quarter of 2017, the company is now using the exchange rates prevailing on September 30, 2017, including a rate of USD 1.18 (previously: USD 1.14) to the euro.

For the Bayer Group, the company is still planning sales of EUR 35 billion to EUR 36 billion for full year 2017. As before, this corresponds to a low-single-digit percentage increase on a currency- and portfolio-adjusted basis. Bayer continues to expect EBITDA before special items to come in slightly above the level of the previous year. As regards core earnings per share from continuing operations, the company now expects a low-single-digit percentage decrease on the basis of the values that were adjusted for Covestro effects for the current year and previous year. This is due primarily to the difference in the number of shares, which grew significantly in 2017 as a result of the mandatory convertible notes issued in November 2016. Without this effect, core earnings per share would improve by a low-single-digit percentage.

For Pharmaceuticals, Bayer now expects sales of approximately EUR 17 billion (previously: more than EUR 17 billion). This continues to correspond to a mid-single-digit percentage increase on a currency- and portfolio-adjusted basis. As before, the company plans to raise sales of its key growth products to more than EUR 6 billion. Bayer continues to expect a high-single-digit percentage increase in EBITDA before special items and an improvement in the EBITDA margin before special items.

For Consumer Health, Bayer continues to expect sales for the full year of about EUR 6 billion. This still corresponds to the prior-year level on a currency- and portfolio-adjusted basis. As before, the company expects EBITDA before special items to decline by a high-single-digit percentage.

For Crop Science, Bayer is still anticipating sales of below EUR 10 billion. This corresponds to a low-single-digit-percentage decline on a currency- and portfolio-adjusted basis. Meanwhile, the company continues to expect EBITDA before special items to decline by a mid-teens percentage.

For Animal Health, Bayer still anticipates a currency- and portfolio-adjusted increase in sales by a low- to mid-single-digit percentage. As before, it plans to improve EBITDA before special items by a high-single-digit percentage.

In 2017, Bayer now expects to take special charges for continuing operations in EBITDA in the region of EUR 0.6 billion (previously: EUR 0.5 billion). Excluding capital and portfolio measures, net financial debt is targeted to be around EUR 4 billion at the end of 2017 (previously: around EUR 7 billion).

Seattle Genetics Reports Third Quarter 2017 Financial Results

On October 26, 2017 Seattle Genetics, Inc. (NASDAQ: SGEN) reported financial results for the third quarter and nine months ended September 30, 2017 (Press release, Seattle Genetics, OCT 26, 2017, View Source [SID1234521217]).

The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development accomplishments, enfortumab vedotin (ASG-22ME) and tisotumab vedotin clinical activities, as well as progress with its pipeline of antibody-drug conjugates (ADCs) and other proprietary programs.

“We have recently delivered on several important goals that continue to strengthen the ADCETRIS brand and advance our portfolio of pipeline programs. The FDA granted Breakthrough Therapy Designation to ADCETRIS in combination with chemotherapy in frontline advanced classical Hodgkin lymphoma based on data from the phase 3 ECHELON-1 clinical trial, and we are on track to submit a supplemental Biologics License Application (BLA) for this indication soon. And, the supplemental BLA for ADCETRIS in cutaneous T-cell lymphoma was filed by the FDA with priority review and a PDUFA date of December 16, 2017,” said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “We have also made significant progress with our pipeline, which now includes two ADCs for which we are pursuing rapid development pathways based on positive FDA feedback. We and our partner Astellas have initiated a pivotal phase 2 trial of enfortumab vedotin in metastatic urothelial cancer, and we and our partner Genmab plan to advance tisotumab vedotin into a pivotal phase 2 trial for recurrent or metastatic cervical cancer in the first half of 2018. We anticipate several additional milestones before the end of 2017, including a strong presence at the American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting in December highlighted by a presentation of our full ECHELON-1 data in frontline Hodgkin lymphoma.”

ADCETRIS Program Highlights

ALCANZA Approval Application: The U.S. Food and Drug Administration (FDA) accepted for filing an ADCETRIS supplemental Biologics License Application (BLA) based primarily on data from the phase 3 ALCANZA trial in patients with CD30-expressing mycosis fungoides and primary cutaneous anaplastic large cell lymphoma, the most common subtypes of cutaneous T-cell lymphoma (CTCL). The FDA granted Priority Review to the application and the Prescription Drug User Fee Act (PDUFA) target action date is December 16, 2017. ADCETRIS previously received FDA Breakthrough Therapy Designation in this setting.
Frontline Hodgkin Lymphoma Breakthrough Therapy Designation: The FDA granted Breakthrough Therapy Designation to ADCETRIS in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma. The designation is based on positive results from the phase 3 ECHELON-1 clinical trial.
ECHELON-1 Approval Application: Seattle Genetics expects to submit in the fourth quarter of 2017 a supplemental BLA to the FDA for approval of ADCETRIS in frontline advanced classical Hodgkin lymphoma.
ECHELON-1 Phase 3 Data at ASH (Free ASH Whitepaper): Data from the ECHELON-1 phase 3 trial were accepted for presentation at the American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting being held December 9-12, 2017 in Atlanta, GA. In addition, more than a dozen other ADCETRIS data sets will be featured during the meeting.
ECHELON-2 Phase 3 Trial: ECHELON-2 is a phase 3 trial in frontline CD30-expressing mature T-cell lymphoma (MTCL), also known as peripheral T-cell lymphoma (PTCL). Data from the trial are expected in 2018.
Long-term Follow-up Data in Systemic ALCL: Seattle Genetics and its partner Takeda announced that final data from an ADCETRIS pivotal phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) were published in the journal Blood. The manuscript, which summarizes the five-year, end-of-study results, highlights durable, long-term remissions in sALCL patients treated with ADCETRIS monotherapy.
ADCETRIS Approval: Takeda continues to receive additional marketing approvals for ADCETRIS, which is now commercially available in 68 countries worldwide following the recent approval in South Africa.
ADCETRIS is not currently approved for use in CTCL, frontline Hodgkin lymphoma or frontline MTCL.

Enfortumab Vedotin Program Highlights

Pivotal Trial Initiated: Seattle Genetics and its collaborator Astellas initiated a pivotal phase 2 trial of single-agent enfortumab vedotin for locally advanced or metastatic urothelial cancer patients who received prior checkpoint inhibitor (CPI) therapy. The single-arm trial is designed to enroll approximately 120 patients and the primary endpoint is confirmed objective response rate per independent review. The trial may support regulatory submission under the FDA’s accelerated approval regulations.
Combination Clinical Trial Planned: Seattle Genetics and Astellas plan to initiate a phase 1b trial of enfortumab vedotin in combination CPI therapies, including pembrolizumab, for first- or second-line treatment of patients with locally advanced or metastatic urothelial cancer.
Tisotumab Vedotin Program Highlights

Co-development Option Exercised: Seattle Genetics exercised its option to co-develop tisotumab vedotin with Genmab, adding an additional ADC for solid tumors to its pipeline. The decision was based on promising data from a phase 1/2 trial conducted by Genmab in solid tumors, including cervical cancer. Going forward, Genmab and Seattle Genetics will co-develop and share all future costs and profits for tisotumab vedotin on a 50:50 basis.
Phase 1/2 Data in Cervical Cancer: Phase 1/2 data were featured in an oral presentation at the European Society for Medical Oncology annual meeting showing that of 34 relapsed, recurrent and/or metastatic cervical cancer patients evaluable for response, 11 patients (32 percent) achieved a response. Median duration of confirmed responses was 8.3 months. The most common adverse events of any grade were conjunctivitis (50 percent), epistaxis, fatigue and alopecia (47 percent each) and nausea (44 percent).
Planned Pivotal Trial: Seattle Genetics and Genmab announced plans to advance tisotumab vedotin into a pivotal phase 2 trial for recurrent or metastatic cervical cancer that relapses or progresses after standard of care treatment for cervical cancer. The single-arm trial is designed to enroll approximately 100 women and potentially could support registration under the FDA’s accelerated approval regulations.
Other Recent Activities

SGN-LIV1A Combination Clinical Trials: Seattle Genetics entered into collaboration agreements to expand the clinical evaluation of SGN-LIV1A in patients with breast cancer. The ADC will be evaluated in combination with pembrolizumab (KEYTRUDA) under an agreement with Merck and as part of a neoadjuvant treatment in the QuantumLeap Healthcare Collaborative’s phase 2 I-SPY 2 trial. Previously, Seattle Genetics entered into a collaboration with Roche for the evaluation of SGN-LIV1A in combination with atezolizumab (TECENTRIQ) as part of the MORPHEUS trial.
SGN-LIV1A Clinical Data: Data from a phase 1 trial of SGN-LIV1A monotherapy were accepted for presentation at the San Antonio Breast Cancer Symposium taking place December 4-9, 2017.
SGN-CD48A IND: An investigational new drug (IND) application was accepted by the FDA for the novel ADC SGN-CD48A. A phase 1 trial is planned in early 2018 for patients with relapsed multiple myeloma.
Manufacturing Facility: In October 2017, Seattle Genetics closed on its transaction to purchase Bristol-Myers Squibb’s state-of-the-art biologics manufacturing facility in Bothell, Washington. Seattle Genetics plans to utilize the facility primarily for antibody production for current and future pipeline programs.
ADC Collaborator Milestone: Seattle Genetics achieved a $12 million milestone payment under its ongoing ADC collaboration with AbbVie triggered by AbbVie’s clinical progress with depatuxizumab mafodotin (ABT-414) for patients with glioblastoma. Depatuxizumab mafodotin is an ADC targeting EGFR utilizing Seattle Genetics’ proprietary technology.
ADC Collaborator Progress: Roche announced that polatuzumab vedotin, an ADC utilizing Seattle Genetics’ technology, received Breakthrough Therapy Designation from the FDA and that a phase 3 trial in diffuse large B-cell lymphoma is planned for the fourth quarter of 2017. The ADC was previously granted PRIME (PRIority MEdicines) designation by the European Medicines Agency.
Third Quarter and Nine Months 2017 Financial Results

Total revenues in the third quarter and nine month periods ended September 30, 2017 increased to $135.3 million and $352.6 million, respectively, compared to $106.3 million and $312.9 million from the same periods in 2016. Revenues included:

ADCETRIS net sales in the third quarter of $79.2 million, a 13 percent increase from net sales of $70.1 million in the third quarter of 2016. For the year-to-date, ADCETRIS sales were $223.8 million, compared to $195.0 million for the year-to-date period in 2016, a 15 percent increase.
Royalty revenues in the third quarter of 2017 of $16.7 million, compared to $12.2 million in the third quarter of 2016. For the year-to-date in 2017, royalty revenues were $46.0 million, compared to $53.7 million for the first nine months of 2016. Royalty revenues are primarily driven by international sales of ADCETRIS by Takeda. Royalty revenues in 2016 included a $20.0 million sales milestone payment from Takeda earned in the first quarter of 2016.
Amounts earned under the company’s ADCETRIS and ADC collaborations totaling $39.4 million in the third quarter and $82.8 million for the first nine months of 2017, compared to $24.0 million and $64.1 million, respectively, for the same periods in 2016.
Total costs and expenses for the third quarter of 2017 were $167.5 million, compared to $138.7 million for the third quarter of 2016. For the first nine months of 2017, total costs and expenses were $503.4 million, compared to $399.7 million in the first nine months of 2016. The increase in 2017 costs and expenses was primarily driven by ADCETRIS drug supply provided to Takeda as well as investment in enfortumab vedotin, SGN-LIV1A and the company’s pipeline programs.

Non-cash, share-based compensation cost for the first nine months of 2017 was $47.9 million, compared to $37.0 million for the same period in 2016.

As part of a previously terminated license transaction with Immunomedics, Seattle Genetics holds 3.0 million shares of Immunomedics common stock and a warrant to purchase an additional 8.7 million shares. In September 2017, Immunomedics’ resale registration statement covering the shares issuable upon exercise of the warrant was declared effective by the SEC. As a result, the warrant is accounted for as a derivative security and marked-to-market. This led to a gain of $78.7 million reflected in investment and other income, net, recorded in the quarter ended September 30, 2017.

Due to the gain on the Immunomedics warrant, Seattle Genetics reported net income in the third quarter of 2017 of $50.0 million, or $0.34 per fully diluted share, compared to a net loss of $31.8 million, or $0.23 per share, for the third quarter of 2016. For the nine months ended September 30, 2017, net loss was $66.3 million, or $0.46 per share, compared to a net loss of $85.0 million, or $0.61 per share, for the nine months period ended September 30, 2016.

As of September 30, 2017, Seattle Genetics had $470.4 million in cash, cash equivalents and investments.

2017 Financial Outlook

Seattle Genetics updated its full year 2017 financial guidance as follows:

Current Previous
Revenues from collaboration and license agreements $90 million to $100 million $75 million to $90 million
Royalty revenues $60 million to $65 million $50 million to $55 million
Research and development expenses $460 million to $480 million $460 million to $500 million
Conference Call Details

Seattle Genetics’ management will host a conference call and webcast to discuss its third quarter 2017 financial results and provide an update on business activities. The event will be held today at 1:30 p.m. Pacific Time (PT); 4:30 p.m. Eastern Time (ET). The live event will be available from the Seattle Genetics website at www.seattlegenetics.com, under the Investors section, or by calling 877-830-2649 (domestic) or 785-424-1824 (international). The conference ID is 4819463. A replay of the discussion will be available beginning at approximately 4:30 p.m. PT today from the Seattle Genetics website or by calling 888-203-1112 (domestic) or 719-457-0820 (international), using conference ID 4819463. The telephone replay will be available until 5:00 p.m. PT on Monday, October 30, 2017.

Cytomx Therapeutics to Announce Third Quarter 2017 Financial Results

On October 26, 2017 CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, reported that it will announce financial results for the third quarter ended September 30, 2017, on November 7, 2017, after the NASDAQ market closing (Press release, CytomX Therapeutics, OCT 26, 2017, View Source [SID1234521211]).

The company will not conduct a conference call in conjunction with this financial results press release.

Juniper Pharmaceuticals to Report Third Quarter 2017 Results on November 2, 2017

On October 26, 2017 Juniper Pharmaceuticals (Nasdaq: JNP) (“Juniper” or the “Company”), reported that it will hold a conference call on November 2, 2017, to discuss the financial results for the third quarter ended September 30, 2017, as follows (Press release, Juniper Pharmaceuticals, OCT 26, 2017, View Source [SID1234521214]):

Date:
Thursday, November 2, 2017
Time:
4:30 p.m.
Dial-in numbers:
Toll free: (1-866-374-4635) (U.S.), (1-855-669-9657) (Canada), or

International: (1-412-902-4218)

Audio webcast (live & archive): www.juniperpharma.com, under ‘Investors’ or click here.

The teleconference replay will be available approximately one hour after completion through Thursday, November 9, 2017, at 1-877-344-7529 (U.S.), 1-855-669-9658 (Canada) or 1-412-317-0088 (International). The replay access code is 10113476.

The archived webcast will be available for one year via the aforementioned URLs.

Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2017 Financial Results on Monday, November 6, 2017

On October 26, 2017 Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, reported that it plans to host a conference call and webcast on Monday, November 6, 2017 at 5:00 p.m. ET to discuss its third quarter 2017 financial results and provide a corporate update (Press release, Keryx Biopharmaceuticals, OCT 26, 2017, View Source [SID1234521215]).

To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 2193619. The call will be webcast live with slides and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.